News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,996 Results
Type
Article (42313)
Company Profile (436)
Press Release (671247)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (208743)
Career Advice (2021)
Deals (36006)
Drug Delivery (104)
Drug Development (83582)
Employer Resources (173)
FDA (16429)
Job Trends (15094)
News (352801)
Policy (33078)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (85)
Alliances (50959)
ALS (94)
Alzheimer's disease (1425)
Antibody-drug conjugate (ADC) (139)
Approvals (16417)
Artificial intelligence (262)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (79)
Brain cancer (26)
Breast cancer (280)
Cancer (2252)
Cardiovascular disease (183)
Career advice (1688)
Career pathing (30)
CAR-T (152)
Cell therapy (430)
Cervical cancer (19)
Clinical research (67726)
Collaboration (862)
Compensation (530)
Complete response letters (24)
COVID-19 (2646)
CRISPR (42)
C-suite (244)
Cystic fibrosis (105)
Data (2161)
Decentralized trials (2)
Denatured (28)
Depression (49)
Diabetes (268)
Diagnostics (6420)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87685)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115700)
Executive appointments (726)
FDA (17668)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (780)
Gene editing (109)
Generative AI (20)
Gene therapy (315)
GLP-1 (743)
Government (4499)
Grass and pollen (4)
Guidances (53)
Healthcare (19144)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (127)
Indications (29)
Infectious disease (2791)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (95)
Interviews (311)
IPO (16782)
IRA (43)
Job creations (3701)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (491)
Leadership (17)
Legal (7986)
Liver cancer (74)
Lung cancer (320)
Lymphoma (152)
Machine learning (6)
Management (58)
Manufacturing (306)
MASH (68)
Medical device (13514)
Medtech (13519)
Mergers & acquisitions (19748)
Metabolic disorders (705)
Multiple sclerosis (79)
NASH (19)
Neurodegenerative disease (98)
Neuropsychiatric disorders (33)
Neuroscience (1980)
NextGen: Class of 2025 (6756)
Non-profit (4547)
Northern California (2639)
Now hiring (39)
Obesity (381)
Opinion (223)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (82)
Parkinson's disease (153)
Partnered (21)
Patents (231)
Patient recruitment (106)
Peanut (47)
People (58638)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21278)
Phase II (29881)
Phase III (22100)
Pipeline (1168)
Policy (143)
Postmarket research (2601)
Preclinical (9103)
Press Release (67)
Prostate cancer (104)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (399)
Real estate (6015)
Recruiting (66)
Regulatory (22712)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (74)
Series A (139)
Series B (89)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2278)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3762)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (33)
The Weekly (48)
United States (23121)
Vaccines (698)
Venture capitalists (43)
Weight loss (252)
Women's health (37)
Worklife (16)
Date
Today (87)
Last 7 days (727)
Last 30 days (2375)
Last 365 days (33777)
2025 (10220)
2024 (36302)
2023 (41016)
2022 (52276)
2021 (56764)
2020 (54920)
2019 (47417)
2018 (35696)
2017 (33028)
2016 (32348)
2015 (38397)
2014 (32189)
2013 (27110)
2012 (29222)
2011 (29866)
2010 (27996)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (39241)
Australia (6527)
California (6083)
Canada (1985)
China (522)
Colorado (268)
Connecticut (280)
Delaware (144)
Europe (85719)
Florida (884)
Georgia (203)
Idaho (57)
Illinois (540)
India (25)
Indiana (309)
Iowa (12)
Japan (159)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (892)
Massachusetts (4622)
Michigan (218)
Minnesota (390)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (66)
New Jersey (1722)
New Mexico (30)
New York (1717)
North Carolina (1018)
North Dakota (7)
Northern California (2639)
Ohio (202)
Oklahoma (14)
Oregon (38)
Pennsylvania (1352)
Puerto Rico (11)
Rhode Island (33)
South America (1110)
South Carolina (22)
South Dakota (1)
Southern California (2278)
Tennessee (101)
Texas (900)
Utah (180)
Virginia (147)
Washington D.C. (63)
Washington State (566)
West Virginia (3)
Wisconsin (53)
713,996 Results for "sirna therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
April 23, 2025
·
5 min read
Press Releases
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
March 31, 2025
·
7 min read
Press Releases
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
April 21, 2025
·
2 min read
Press Releases
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia
March 17, 2025
·
2 min read
Press Releases
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
December 18, 2024
·
3 min read
Press Releases
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany
April 3, 2025
·
4 min read
Press Releases
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
January 7, 2025
·
5 min read
Genetown
Aphios Granted US Patent For siRNA Targeted Therapeutics for Treatment of HIV-1 and Other Diseases
Aphios Corporation announced today that it has been granted US Patent No. 11,981,174 for CCR5 and CD4 siRNA-targeted therapeutics for treatment of HIV-1 and other diseases.
May 15, 2024
·
2 min read
Press Releases
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
November 26, 2024
·
10 min read
Press Releases
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
-Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration
April 9, 2025
·
4 min read
1 of 71,400
Next
